5-fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma
Article Abstract:
The adrenal gland is actually two distinct glands with different functions. While cancers of the adrenal medulla are common, cancers of the adrenal cortex are extremely rare. When they do occur, adrenal cortical cancers are aggressive and neither surgery nor chemotherapy offer more than temporary relief. Furthermore, the secretion of steroids by the cancerous tissues may make the disease particularly unpleasant. A study was undertaken to evaluate the usefulness of a chemotherapeutic drug combination in the treatment of adrenal cortical cancer. Fourteen patients were treated with a combination of 5-fluorouracil, doxorubicin, cisplatin. At the time of treatment, all patients had rapidly progressive cancer and a large tumor burden, that is, they were already carrying an especially large mass of cancerous tissues. Of the 13 patients available for follow-up, only one achieved a complete response. This patient lived without symptoms for 42 months until the reappearance of metastatic cancer in the lungs which led to the patient's death. Of the remaining patients, two patients had partial responses which lasted for 6 and 11 months. In an additional two patients, the rapid progression of the cancer was halted; this stabilization of disease lasted four and six months. The results indicate that the combination of 5-fluorouracil, doxorubicin, and cisplatin is as effective in the treatment of adrenal cortical cancer as any other treatment that has been evaluated to date. However, the present study was too small to determine if the combination used might be more effective than either cisplatin or doxorubicin used separately. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: Cancer
Subject: Health
ISSN: 0008-543X
Year: 1991
User Contributions:
Comment about this article or add new information about this topic:
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma: a phase II randomized study with cisplatin and etoposide as the control arm
Article Abstract:
The combination of cisplatin and etoposide (PE) is one of the standard treatments for non-small cell lung cancer. Although numerous attempts have been made to improve the response rate by adding a third drug to the combination, a protocol more effective than PE has not been found. In a Phase II randomized trial, the effectiveness of ifosfamide as a possible third agent was evaluated. Thirty-nine patients received only PE, and 39 received cisplatin, etoposide, and ifosfamide (PEI). The response rates of both groups was similar. The average survival times were also similar, at six months for PEI, and seven months for PE. The results suggest that the addition of ifosfamide to the standard PE treatment for non-small cell lung cancer provides no advantage. (Consumer Summary produced by Reliance Medical Information, Inc.)
Publication Name: Cancer
Subject: Health
ISSN: 0008-543X
Year: 1990
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A 72-year-old woman with bronchospasm and pleural effusion after treatment of breast carcinoma. A 49-year-old woman with primary biliary cirrhosis, pulmonary opacities, and a pleural effusion
- Abstracts: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms